Investment
Features
FeesSafety
Academy
More
Pluang+

Ocean Power Technologies tests WAM-V 8 autonomous vehicle in tough surf conditions for near-shore use

Market News
18 Sep 2026
Proactive Investors
View Source
Bullish
Ocean Power Technologies tests WAM-V 8 autonomous vehicle in tough surf conditions for near-shore use

Ocean Power Technologies conducted a formal demonstration of its WAM-V 8 autonomous vehicle in challenging surf-zone conditions at the US Army Corps of Engineers' research facility in North Carolina. The test evaluated sensor performance, vehicle setup, and sensor deployment, providing valuable data to improve their 16- and 22-foot WAM-V platforms for near-shore environments. Insights from this trial will guide design enhancements and operational safety improvements to better meet customer needs. The company thanked the USACE and research teams for enabling the evaluation.

Ocean Power Technologies' WAM-V 8 platform demonstration is the subject, with Pluang market data as context for readers. As of Sep 18, 2026 18:51 WIB, out of 150 priced Technology-sector US stocks tradable on Pluang, 71 rose and 71 fell. Notable movers include GLW at USD 150.29 with a 1-day change of +1.75%, BTDR at USD 11.43 up +1.69%, and NOK at USD 10.78 rising +1.60%.

More News

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
46 minutes ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
1 hour ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
2 hours ago
Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays lowered its price target for Lennar Corporation to $70 from a higher level, citing a 52% drop in Q3 net earnings to $284 million and an 8.6% revenue decline to $8.05 billion. The homebuilder faces headwinds from rising mortgage rates and wea...

Analyst Insights
Bearish
2 hours ago
Guggenheim raises price target for Restaurant Brands International to $86 amid growth and share buybacks

Guggenheim raises price target for Restaurant Brands International to $86 amid growth and share buybacks

Guggenheim has raised its price target for Restaurant Brands International (QSR) to $86 from $85 and reiterated a Buy rating, reflecting confidence in the company's strategic growth. Restaurant Brands International is enhancing shareholder value thro...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App